Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SXC 2023

Next Previous
Search
Drug Profile

SXC 2023

Alternative Names: SXC-2023

Latest Information Update: 29 Nov 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Marquette University; University of Wisconsin at Milwaukee
  • Developer Promentis Pharmaceuticals
  • Class Neuropsychotherapeutics; Small molecules
  • Mechanism of Action SLC7A11 protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Impulse control disorders

Most Recent Events

  • 11 Oct 2024 National Institute on Drug Abuse in collaboration with Promentis Pharmaceuticals initiates a phase I trial for Impulse control disorders in the US (NCT06343532)
  • 02 Apr 2024 National Institute on Drug Abuse in collaboration with Promentis Pharmaceuticals plans a phase I trial for Cocaine-related disorders in the US (NCT06343532)
  • 17 Mar 2021 Phase II development for Impulse control disorders is still ongoing in USA (Promentis Pharmaceuticals pipeline, March 2021)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top